TABLE 1.
Frequencies of papilloma formation and regression in rabbits vaccinated with the E6 gene, using no augmentation, GM-CSF priming, or ubiquitin fusion
| Augmentation | Antigen | Nd | Frequency off:
|
|||||
|---|---|---|---|---|---|---|---|---|
| Formationa
|
Regressionb
|
Final frequencyc
|
||||||
| No. | Percentage | No. | Percentage | No. | Percentage | |||
| Nonee | β-gal | 10 | 50/50 | 100 | 0/50 | 0 | 50/50 | 100 |
| E6 | 13 | 65/65 | 100 | 1/65 | 2 | 64/65 | 98 | |
| GM-CSF | β-gal | 3 | 15/15 | 100 | 0/15 | 0 | 15/15 | 100 |
| E6 | 5 | 22/25 | 88 | 7/22 | 32 | 15/25 | 60* | |
| Ubiquitin | β-gal | 3 | 15/15 | 100 | 1/15 | 7 | 14/15 | 93 |
| E6 | 5 | 13/25 | 52* | 9/13 | 69* | 4/25 | 16** | |
a
Maximum number of sites that ever formed a papilloma/total number of sites.
b
Number of papillomas that completely regressed/number that formed.
c
Final number of papillomas/total number of sites.
d
N, number of rabbits per group.
e
The nonaugmented control group consisted of rabbits vaccinated with the β-gal gene after priming with pcDNA3 (N = 2) or pCMV-β (N = 3) and rabbits that were both primed and vaccinated with pcDNA3 (N = 2).
f
∗, significant at P ≤ 0.05; ∗∗, significant at P = 0.001.